• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Monday 07/23/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

diabetes

  • 1:09 PM

    LOUISVILLE, CO–ANTB, (Marketwired – July 17, 2017) – AntriaBio, Inc. (“AntriaBio or the “Company”) (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today that it has closed on a total of $13 million as part of a planned private placement transaction. Under the terms of the financing, accredited investors paid $1.00 for one share of common stock. The amount raised to date includes investments made

    Read more
  • 4:42 PM

    LAGUNA HILLS, Calif., Nov. 29, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has been granted by the FDA. During the meeting with representatives from CBER, they will respond to PharmaCyte’s previously

    Read more
  • 3:23 PM

    LAGUNA HILLS, Calif., Sept. 01, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on its program for developing treatments for serious brain cancers that involve constituents of the Cannabis plant. These Cannabis-based cancer therapies, like PharmaCyte’s pancreatic cancer therapy, will involve the use of its Cell-in-a-Box® technology. The cancer “prodrug” that will be activated

    Read more
  • 3:12 PM

    SILVER SPRING, Md., May 03, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor. Dr. Sanjay Batra brings to PharmaCyte more than 20 years of global healthcare and entrepreneurial experience in start-ups, biotech and large pharma. Dr. Batra spent 10 years at Johnson &

    Read more
  • Dario Logo
    7:02 PM

    – FDA clearance announced on December 22nd – 61% increase in sequential quarterly shipments – Q4 2015 net loss and operating loss narrowed by 9% and 27%, respectively, compared to Q3 2015 – 694% increase in annual shipments – 2015 net loss narrowed by 45% compared to 2014 – Rapid market penetration and favorable user experience PR Newswire, DRIO CAESAREA, Israel, Feb. 9, 2016 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, reported financial and

    Read more
  • Dario Logo
    3:38 PM

    CAESAREA, Israel, January 26, 2016, DRIO, /PRNewswire/ — Sales channels to include direct-to-consumer, e-commerce, third-party distributors Establishing North American headquarters and warehouse to serve U.S. and Canada LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today announced it is preparing to launch its FDA-cleared product in the United States in the first quarter of 2016. The national rollout in the U.S. follows the FDA’s 510(k) clearance of the Dario in December 2015. Direct-to-consumer sales through

    Read more
Public Wire Banner